Tessera Therapeutics reports infusion gene edit corrects 85% of blood cells in sickle cell study

Tessera Therapeutics announced new data from its in-vivo gene editing program targeting sickle cell disease.

The experimental therapy is given as a simple infusion, avoiding the complex cell engineering and chemotherapy conditioning required by current cell‑based cures.

In the study, the infusion edited roughly 85% of circulating blood cells, indicating a high level of genetic correction.

Researchers suggest the results could make the approach an off-the-shelf alternative to existing commercial cell therapies for sickle cell patients.